Adherence and patients’ experiences with erlotinib.

Adherence and patient'experiences with the use of erlotinib in NSCLC treatment: the influence on plasma concentration and the exploration of factors affecting the use in daily practice.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON26332

Enrollment

Registered

2009-05-25

Start date

2009-07-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Oral chemotherapy Erlotinib Adherence Plasma concentration Longkanker Orale chemotherapie Erlotinib Therapietrouw Plasmaconcentratie

Interventions

None, this is an observational study. The use of erlotinib in daily practice will be monitored for 4 months.

Eligibility

Inclusion criteria

Inclusion criteria: NSCLC patients starting with erlotinib.

Exclusion criteria

Exclusion criteria: Younger than 18 year or insufficient knowledge of the Dutch language.

Design outcomes

Primary

Measure	Time frame
1. Adherence rate; a patient is adherent with the intake of 85% or more of the prescribed medication; 2. Plasma concentration of erlotinib; 3. Number and grade of side-effects.	—

Secondary

Measure	Time frame
1. Quality of life; 2. Attitude towards disease; 3. Beliefs and attitude towards medicines; 4. Percentage of dose adjustment; 5. Discontinuation.	—

Contacts

Public ContactL. Timmers

+31 (0)20 4442777

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)